New Delhi, Feb. 3 -- Alembic Pharmaceuticals posted its results for the quarter ended December 2024 (Q3FY25). Its consolidated net profit tumbled 23.29 percent to Rs.138.42 crore in Q3 FY25, compared with Rs.180.45 crore posted in Q3 FY24. However, revenue from operations was at Rs.1,692.74 crore in the third quarter of FY25, up 3.81 percent year on year (YoY).

EBITDA increased by 1 percent YoY to Rs.271 crore, with an EBITDA margin of 16 percent in Q3 FY25.

On the segmental front, API revenue stood at Rs.259 crore, reflecting a 10 percent year-on-year decline, primarily due to muted demand from select customers and pricing pressures. However, the company remains optimistic about a rebound in the coming quarters, supported by a robust o...